Journal
CURRENT DIABETES REPORTS
Volume 16, Issue 6, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0745-3
Keywords
MicroRNA; Therapeutics; Anti-sense oligonucleotide; Diabetes; Metabolic disease; Aptamer
Categories
Funding
- NIDDK/NIH [R01DK105965]
- American Diabetes Association [1-16-ACE-47 Pathway]
Ask authors/readers for more resources
MicroRNAs (miRNAs) are small, non-coding, RNA molecules that regulate gene expression. They have a long evolutionary history and are found in plants, viruses, and animals. Although initially discovered in 1993 in Caenorhabditis elegans, they were not appreciated as widespread and abundant gene regulators until the early 2000s. Studies in the last decade have found that miRNAs confer phenotypic robustness in the face of environmental perturbation, may serve as diagnostic and prognostic indicators of disease, underlie the pathobiology of a wide array of complex disorders, and represent compelling therapeutic targets. Preclinical studies in animal models have demonstrated that pharmacologic manipulation of miRNAs, mostly in the liver, can modulate metabolic phenotypes and even reverse the course of insulin resistance and diabetes. There is cautious optimism in the field about miRNA-based therapies for diabetes, several of which are already in various stages of clinical trials. This review will highlight both the promise and the most pressing challenges of therapeutic miRNA silencing in diabetes and related conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available